Who is sponsoring NCT02047500?

NCT02047500 is sponsored by ImmunoGenesis.

What condition does NCT02047500 study?

NCT02047500 studies Pancreatic Cancer.

What drugs are being tested in NCT02047500?

Interventions: TH-302, Nab-paclitaxel, Gemcitabine.

What is the status of NCT02047500?

NCT02047500 is currently TERMINATED.

Last reviewed 2025-05-08 · How we verify

An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

NCT02047500 Phase 1 TERMINATED Results posted

This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma.

Details

Lead sponsor	ImmunoGenesis
Phase	Phase 1
Status	TERMINATED
Enrolment	19
Start date	2014-01
Completion	2016-05

Conditions

Pancreatic Cancer

Interventions

TH-302
Nab-paclitaxel
Gemcitabine

Primary outcomes

Number of Subjects Experiencing Dose Limiting Toxicity (DLT) — Up to Day 28 of Cycle 1

Countries

United States